Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells - Wikidata - awgldk - TriplyDB

Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells

Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells

http://www.wikidata.org/entity/Q33638864

about

Circulating tumor cells in breast cancer: a tool whose time has come of age Circulating tumor cells: approaches to isolation and characterization The promise of circulating tumor cell analysis in cancer management Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells PARP inhibitor treatment in ovarian and breast cancer Molecular biomarker analyses using circulating tumor cells Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream® system.The nuclear γ-H2AX apoptotic ring: implications for cancers and autoimmune diseases.Bridging Plant and Human Radiation Response and DNA Repair through an In Silico Approach.Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker.Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.γ-H2AX and other histone post-translational modifications in the clinic.DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.Circulating tumor cells in non-small cell lung carcinoma Considerations in the development of circulating tumor cell technology for clinical use Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy Progress in using circulating tumor cell information to improve metastatic breast cancer therapy Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.Physical biology in cancer. 2. The physical biology of circulating tumor cells.Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.Targeted therapy for triple-negative breast cancer: where are we?PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.H2AX a promising biomarker for lung cancer: a review.Circulating tumor cells, enumeration and beyond.Molecular analysis of circulating tumour cells-biology and biomarkers.Translational research in oncology--10 years of progress and future prospects.Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.DNA damage of glioblastoma multiform cells induced by Beta radiation of iodine-131 in the presence or absence of topotecan: a picogreen and colonogenic assay

P2860

Q21245253-4A30AC4D-0F3A-43F9-9CAA-3401370EC744 Q24631347-6B741A1E-F73C-4DD8-A4E8-71B95D5C5664 Q27022113-48D99A81-5C71-4EE7-8364-9D0FDB11106C Q27023686-922E095F-76B5-4B8C-ADE3-66CAD4F0E495 Q28257534-680C4D18-065C-4E15-B4A7-231A16AD4E96 Q28741688-A0C2D4B5-C542-4068-949D-3C4DC9441614 Q28749394-6C46B57C-C6D9-4A46-92AF-A6F9DAB0D3A7 Q31006508-E88A57B3-D4EA-4BFE-9AAE-4D5ADF9FACD2 Q33558772-7DB1590F-D926-4D82-972B-8E611E5B78F3 Q33656349-43A0013B-9271-4270-B4F0-C078A1BA4AB7 Q33832761-B5F173A5-A3B3-4A2A-A0D3-955B8494F169 Q33897223-B170C4FE-BDB3-4639-BDDC-459793F4A84C Q34134483-4166D17F-B549-4514-A827-8DA4CCF29C22 Q34316288-137BD53E-3F3D-4E0B-B5F8-0591F387A1CC Q34531543-F421E08F-39A5-460C-AD15-7C1F2EBFA7AE Q34852332-EEF6D8E3-B236-4798-95EE-170D0F0FB217 Q35195304-0C84798F-D30D-4B8B-9D7B-AC5C835024D5 Q35251489-8BD7EAC7-06CD-4A73-B58D-55F971D4B3E4 Q35836463-8B4A79FC-836A-422B-9F65-65447A81B04D Q36019818-1F947DFB-3398-4CAF-A928-DF29053DF171 Q36073749-F2212AF9-7457-4B00-9623-83E1F0A825CA Q36287629-B5180AA0-EA56-4CFA-8F1C-8E378F2C5BE5 Q36338628-917AB13F-5A44-49E2-B4EE-396BB9AC0A67 Q36345878-7C6A99FB-8E2D-4333-92E9-0B23F67FF224 Q36752761-861DC1F6-6018-49CC-A4C4-4520C4704B26 Q36880037-001EB094-265A-4419-B8BD-65331ED43A56 Q37544686-CD9C02B9-9AB1-4DD7-9ADE-CF727CB10BBD Q37575309-F8C28413-570E-4A26-96E7-590687F1A3F6 Q37826009-0B2984AD-D5BA-4E5A-9192-9A0525DBA1F2 Q38009760-B94E0FCE-9329-4D04-A6A3-C64CB700E6C3 Q38029726-5D37447F-B402-464B-AD6A-6FDC499BF223 Q38155902-184D5647-D6DA-446B-AE25-420D46D636E8 Q38166574-38DCFF7F-98F1-422E-9D95-68B5427EA671 Q38180320-C2F4015C-4E23-4F9E-9EA1-EB6D65FCA823 Q38257126-028D1B91-1611-4CF1-9ACD-BEF7670CB340 Q38905865-AE2FEEB8-858E-4549-8254-EADB4F4AF3AD Q38907580-12F445F4-12FA-4BA0-AD5D-56DE47C4F804 Q38963129-D19D620E-EC81-48FE-A5B3-C0B94F51335C Q38997280-32183195-A7FF-4462-9514-E94C87CA005B Q39527014-B4DC424C-20C2-48D4-9FC5-89619D4E27E8

P2860

Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells

http://www.wikidata.org/entity/Q33638864

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Monitoring drug-induced gammaH ...... vidual circulating tumor cells

@ast

Monitoring drug-induced gammaH ...... vidual circulating tumor cells

@en

type

label

Monitoring drug-induced gammaH ...... vidual circulating tumor cells

@ast

Monitoring drug-induced gammaH ...... vidual circulating tumor cells

@en

prefLabel

Monitoring drug-induced gammaH ...... vidual circulating tumor cells

@ast

Monitoring drug-induced gammaH ...... vidual circulating tumor cells

@en

P1433

Q33638864-ABE6FB5D-ED9A-4B7F-AF21-E0799A56F5E0

P1476

Q33638864-12DCF1FD-3090-4284-BDB6-7727D2C120A8

P2093

Q33638864-0B23CE63-19FC-4CA1-8D64-E70EECE0E5C2

Q33638864-36569929-C7C7-4E93-9DA7-CC0986EEE872

Q33638864-6AAB08EC-051A-43BB-A239-268751F3D4C7

Q33638864-8471BE89-8EEB-4860-9606-7B9AB914B082

Q33638864-879F0D87-7E44-40E5-AC3A-24FE8E70CE4C

Q33638864-A6BB3EC6-CF0C-4E63-A012-10B4A3011B48

Q33638864-AB2731CC-69D1-4E06-9ABF-F221A5FFD79A

Q33638864-BA30356E-21A8-4F1F-85F4-F26F68FD4E9D

Q33638864-D88616D8-1EA3-45FA-8299-3636D6836E91

Q33638864-DEEAC6E6-4859-4FCA-8C38-1B032144BB6D

P2860

Q33638864-01D27604-3EA7-44B4-932D-E9D0262EB241

Q33638864-08FD9880-05CE-4DBB-99FE-9B4F46536740

Q33638864-114AAE9B-E987-4123-8D86-FA73A0ACDAE9

Q33638864-12F829A9-6370-4B9E-8C00-E32BEC039889

Q33638864-17EEB044-3C38-4BBD-B227-3DA3B1225BEB

Q33638864-1E48D245-F980-4B10-AA34-2FF08C0D59A4

Q33638864-209E06CF-9759-44E4-8C60-C2A4FCCA25E5

Q33638864-20CE14DB-1453-4459-85AD-FDA7CE437BA7

Q33638864-21751AF4-C405-43D9-A9A9-5917442C3054

Q33638864-2D874EDD-CC38-48FC-802C-FB0616CC3955

P304

Q33638864-F8ABC7DB-C309-4810-A39F-FB620E89825F

P31

Q33638864-33EBCF30-FC9B-44C6-9ED5-2CDE5E599038

P356

Q33638864-D3E3C9E0-7091-483D-9861-C6703DF7F36B

P407

Q33638864-4EE3AC39-766D-49AF-ADE1-08F80E730C6C

P433

Q33638864-3DDEE0E1-4070-4597-8AA2-4B062B76E1D2

P478

Q33638864-6FE22AE3-657D-4EDE-B307-4CBA7DBAEEC5

P577

Q33638864-F47709FA-B95F-497F-B47B-1310EC064A3B

P5875

Q33638864-69938EED-CCC4-45D4-8D1D-C75EF44F04A5

P698

Q33638864-B71E5E3B-AE16-4B58-8449-E01B42E53180

P921

Q33638864-82CF8DB6-4C9B-4A0F-B335-9FFF2EBE2587

P932

Q33638864-3A03877F-4090-4FDF-905B-C58D1F895D50

P356

1078-0432.CCR-09-2799

P1433

Clinical Cancer Research

P1476

Monitoring drug-induced gammaH ...... vidual circulating tumor cells

@en

P2093

Anthony J Murgo

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Joseph E Tomaszewski

http://www.w3.org/2001/XMLSchema#string

Larry Rubinstein

http://www.w3.org/2001/XMLSchema#string

Lihua H Wang

http://www.w3.org/2001/XMLSchema#string

Martin E Gutierrez

http://www.w3.org/2001/XMLSchema#string

Ralph E Parchment

http://www.w3.org/2001/XMLSchema#string

Robert J Kinders

http://www.w3.org/2001/XMLSchema#string

Shivaani Kummar

http://www.w3.org/2001/XMLSchema#string

Thomas D Pfister

http://www.w3.org/2001/XMLSchema#string

P2860

HER-2 gene amplification can be acquired as breast cancer progresses

A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage

Histone H2A variants H2AX and H2AZ

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

Topoisomerase I inhibitors: camptothecins and beyond

Detection of mutations in EGFR in circulating lung-cancer cells

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.

Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

P304

1073-1084

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-2799

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41148667

http://www.w3.org/2001/XMLSchema#string

P698

20103672

http://www.w3.org/2001/XMLSchema#string

P921

P932

2818670

http://www.w3.org/2001/XMLSchema#string